News

NEWS

The crucial role of activated mast cells in the acute Covid-19 hyperinflammation and post Covid-19 illness (“Long Covid”) has been meanwhile highly recognized. MCS1010 is positioned as likely highly effective additional treatment for acute Covid-19 to limit the cytokine storm, and also for the (preventive) treatment of post Covid-19 illness that is strongly increasing. MCS1010 would be ready for clinical studies for potential partners.

MCS1010 showed significant efficacy in a in-vivo test with excellent safety profile in a selected rare disease indication (as part of one of our primary lead series).

Novel mast cell target successfully identified in human TEVC Oocytes model. Based on identified novel mast cell target futher in-silico optimization has been achieved leading to multiple primary chemical lead series.

Novel mast cell target successfully identified in human TEVC Oocytes model. Based on identified novel mast cell target the further in-silico optimization has been achieved leading to multiple primary chemical lead series.

Together with our scientific research partner NMI Naturwissenschaftliches and Medizinisches Institut an der Universität Tübingen establishment of an Oocytes ePhys Model to express and validate our novel target.

Akkordeon Inhalt

Together with our research partners, MC Sciences has successfully established an ex-vivo mast cell activity model based on living human tissues. Our lead compounds show the expected significant inhibition of mast cell activity (measured by tryptase release activity).

Together with our univesity clinic research partner, MC Sciences has successfully established an ex-vivo mast cell activity model based on living human tissues. Our lead compounds show the expected significant inhibition of mast cell activity (measured by tryptase release activity).

Reproduction and confirmation of pharmacological activity of pharmacophore-derived molecules in murine mast cell and human mast cell in-vitro models.

Agreement on collaboration with Evotec, a worldwide leading and highly recognized CRO, and start of a joint target deconvolution and chemical optimization project.

Discovery of a strong hypothesis of our novel mast cell target that acts as master regulatory of mast cell activation based on evolutionary comparative mRNA expression analysis on human mast cells with mast cells in various species branching from the evolutionary tree 500 million years ago.

MCS1010 showed significant efficacy in a first human in-vivo test with excellent safety profile in a selected rare disease indication (as part of one of our primary lead series).

Novel mast cell target successfully identified in human TEVC Oocytes model. Based on identified novel mast cell target futher in-silico optimization has been achieved leading to multiple primary chemical lead series.

Together with Evotec, the successful chemical hit expansion has been achieved leading to multiple potential chemical optimization routes for the further chemical optimization of our MCS10XX lead series.

Together with our scientific research partner NMI Naturwissenschaftliches and Medizinisches Institut an der Universität Tübingen establishment of an Oocytes ePhys Model to express and validate our novel target.

Akkordeon Inhalt
Akkordeon Inhalt

Together with our research partners, MC Sciences has successfully established an ex-vivo mast cell activity model based on living human tissues. Our lead compounds show the expected significant inhibition of mast cell activity (measured by tryptase release activity).

Together with our univesity clinic research partner, MC Sciences has successfully established an ex-vivo mast cell activity model based on living human tissues. Our lead compounds show the expected significant inhibition of mast cell activity (measured by tryptase release activity).

Reproduction and confirmation of pharmacological activity of pharmacophore-derived molecules in murine mast cell and human mast cell in-vitro models.

Agreement on collaboration with Evotec, a worldwide leading and highly recognized CRO, and start of a joint target deconvolution and chemical optimization project.

Discovery of a strong hypothesis of our novel mast cell target that acts as master regulatory of mast cell activation based on evolutionary comparative mRNA expression analysis on human mast cells with mast cells in various species branching from the evolutionary tree 500 million years ago.